Connect with us


Spanish Biotech Companies Raise 228 Million in Private Financing in 2023

In 2023, Spanish biotech companies secured 228 million euros in private financing, a 37% increase from 2022. This was announced at the AseBio Investor Day, organized by the Spanish Association of Biocompanies. The average operation volume was 5.4 million euros. The event aimed to connect life sciences investors with Spanish biotech firms, attracting 280 attendees from 19 countries.



Spanish biotech companies

Spanish biotech companies raise 228 million euros of private financing in 2023, 37% more than the previous year, as announced in the fifth edition of the AseBio Investor Day, organized by the Spanish Association of Biocompanies (AseBio) in the Kursaal of San Sebastián, with the support of the Provincial Council of Gipuzkoa and ICEX Spain Export and Investment.

AseBio has advanced the new financing data for the biotechnology sector, which has reached 228 million euros in private investment, a figure that represents an increase of 37% compared to the total volume raised in 2022.

These data are part of the AseBio 2023 Report that is will be published on June 12, according to which the average volume of operations has been 5.4 million euros. In 2020, four operations were carried out that exceeded ten million euros, in 2021 five, in 2022 three, and in 2023 five. The number of operations has decreased to 42 compared to 2022.

Part of these operations have been accompanied by Cdti’s Innvierte program, which has committed almost 29 million euros in 2023. Since the launch of this co-investment instrument in 2019, it has committed a total of 101 million euros to 35 Spanish biotech companies.

In this sense, the number of capital increases with the participation of international investors is close to 150 million euros in volume raised. A total of ten companies have had the support of investors from countries such as the United States, the United Kingdom, France, Norway, Sweden, Denmark and Italy.

AseBio pointed out that the average volume of Spanish biotech companies operations has been 5.4 million euros

Likewise, a total of eleven Spanish biotech companies, through eleven operations, have achieved 12.3 million euros through crowdfunding, through the Fellow Funders platform and, mainly with Capital Cell. These figures translate into an increase compared to the previous year in terms of volume captured of 41%. Four companies (Pharmamel, IDP Pharma, Laminar Pharmaceuticals and Oncostellae) have exceeded one million euros through this type of platforms.

The main objective of AseBio Investor Day is to promote access to financing by connecting the main national and international investors specialized in life sciences to Spanish biotech companies. This year, the event brought together nearly 280 attendees from more than 180 entities from 19 countries, including 70 investors from more than 55 investment entities.


(Featured image by Mufid Majnun via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.